Use of masitinib mesylate as an adjuvant treatment of metastatic canine mast cell tumor / Utilização do mesilato de masitinibe no tratamento adjuvante do mastocitoma canino metastático
Horta, Rodrigo dos Santos; Lavalle, Gleidice Eunice; Costa, Mariana de Pádua; Carneiro, Rubens Antônio; Paes, Paulo Ricardo de Olveira; Araújo, Roberto Baracat de.
Acta sci. vet. (Online);
42(suppl.1): Pub. 38, 16 jan. 2014. ilus, tab
Artigo
em Português
| VETINDEX
| ID: vti-31020
Resumo
Background: The proliferative disorders of mast cells include, in addition to mast cell tumor, systemic mastocytosis and myeloid leukemia of mast cells. Surgery is the treatment of choice for tumors in the skin, in regions which allow wide excision but adjuvant treatments should be performed in selected patients. However, the use of adjuvant chemotherapy remains empirical, due to the absence of controlled studies. Despite the relevance of the use of tyrosine kinase inhibitors for the treatment of mast cell tumors, studies with these drugs have focused primarily on neoadjuvant scenery. Case: A 13-year-old male Poodle dog, weighing 4.6 kg, was presented with bilateral increase in inguinal lymph nodes and a vesicular cutaneous lesion, in the inguinal region, 75 days after surgery for the removal of a scrotum grade II mast cell tumor. Patient was admitted for surgery and the tissues removed were sent for pathological examination that allowed the diagnosis of grade II mast cell tumor and metastasis in all inguinal lymph nodes. The immunohistochemical study for CD117 revealed an aberrant expression of KIT receptor (KIT II), while the PCR for mutations in exon 11 of c-KIT gene revealed internal tandem duplications. The patient underwent a session of chemotherapy with lomustine, however it had serious side effects that resulted in discontinuation of treatment, opting for utilization...(AU)
Biblioteca responsável:
BR68.1
Localização: BR68.1
Texto completo